Sangamo Therapeutics, Inc. (SGMO) — Stock Score Summary

Sangamo Therapeutics, Inc. (SGMO) has a MoatMap StockRank of 2/100 based on Quality (9/100), Value (47/100), and Momentum (17/100) factor scores. The current signal is STRONG SELL. A clinical-stage genomic medicine company with high cash burn and no commercialized platform; it does not fit the CDMO pricing power theme.

Sangamo Therapeutics, Inc. is a genomic medicine company focused on developing gene therapies, cell therapies, and *in vivo* genome editing technologies using its proprietary zinc finger nuclease (ZFN) platform. The company is at the forefront of genetic medicine, aiming to address a range of genetic diseases through precise genome modification. Sangamo maintains a strategic competitive position through its extensive intellectual property and collaborative partnerships with major pharmaceutical firms.

Key Financial Metrics

Price$0.15
Market Cap$87M
P/E (Forward)41.90
Price/Book-4.55
Return on Invested Capital-625.1%
Gross Margin-226.0%
Operating Margin-2215.4%
Revenue Growth-77.6%
Free Cash Flow$-47M

Sangamo Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Sangamo Therapeutics, Inc.’s (SGMO) StockRank?
MoatMap’s StockRank for Sangamo Therapeutics, Inc. (SGMO) is 2/100, with a Strong Sell signal. It is a composite of Quality (9), Value (47), and Momentum (17) factor ranks across MoatMap’s 19,000+ stock universe.
Does Sangamo Therapeutics, Inc. have an economic moat?
Sangamo Therapeutics, Inc. (SGMO) has a Quality factor score of 9/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Sangamo Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Sangamo Therapeutics, Inc. (SGMO) is Strong Sell, based on a StockRank of 2/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Sangamo Therapeutics, Inc. in?
Sangamo Therapeutics, Inc. (SGMO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksSGMO deep dive reportAI ChampionsHow we score stocksSense-check another stock